Improvement of virological methods- Is it possible to predict the - - PowerPoint PPT Presentation

▶
improvement of virological methods is it possible to
SMART_READER_LITE
LIVE PREVIEW

Improvement of virological methods- Is it possible to predict the - - PowerPoint PPT Presentation

Feb 11, 2024 128 likes •308 views

Improvement of virological methods- Is it possible to predict the outcome of DAA treatment in HCV patients? Sandra Ciesek 06.05.2017 Outline - A new in vitro model to predict DAA response? - HCV genotyping Are all results correct? Folie 2

slide-1
SLIDE 1

Improvement of virological methods- Is it possible to predict the outcome of DAA treatment in HCV patients?

Sandra Ciesek 06.05.2017

slide-2
SLIDE 2

Folie 2 Titel

Outline

  • A new in vitro model to predict DAA response?
  • HCV genotyping – Are all results correct?
slide-3
SLIDE 3

Folie 3 Titel

Hepatitis C Virus

Modifiziert von Pietschmann, Steinmann & Ciesek, DMW 2008

Familie: Flaviviridae Spezies: Hepatitis C virus (7 Genotypen) Genom: (+) ssRNA, ~ 9.6 kb

Viruspartikel Replikase Komplex

slide-4
SLIDE 4

Folie 4 Titel

Natural occuring HCV can not infect Huh-7.5 cells in cell culture

Chimpanzee Mouse Human PHH, Huh-7.5

slide-5
SLIDE 5

Folie 5 Titel

JFH-1 ist the only isolate which forms infectious particles in cell culture

Huh-7.5 naïve Huh-7.5

Wakita & Pietschmann, Nat Med 2005; Lindenbach, Science 2005; Zhong, PNAS 2005

chimpanzee JFH-1 RNA

slide-6
SLIDE 6

Folie 6 Titel

Is there a method to predict the outcome af antiviral treatment in HCV?

Antibiogram/ Resistogram Natural occurring HCV isolates Huh-7.5

slide-7
SLIDE 7

Folie 7 Titel

  • M. Saeed et al. Nature 2015

Sec14L2 allows replication of natural occuring isolates in Huh-7.5 cells

slide-8
SLIDE 8

Folie 8 Titel

Not all isolates replicate in Huh-7.5 Sec14L2 cells

S e ru m d e riv e d H C V re p lic a tio n in H u h -7 .5 e x p re s s in g S E C 1 4 L 2

P a tie n t s e ru m s a m p le id e n tifie r (g e n o ty p e ) H C V R N A c o p y n u m b e r/n g to ta l R N A

4 6 ( 3 a ) 4 6 2 ( 3 ) 4 6 3 ( 3 a ) 4 7 2 ( 3 a ) 4 7 3 ( 3 a ) 4 7 ( 1 a ) 4 7 1 ( 1 a ) 4 8 ( 1 a ) 4 8 3 ( 1 b ) 4 8 5 ( 1 b ) 4 8 8 ( 1 b ) 4 8 9 ( 1 b ) 1 0 -2 1 0 -1 1 0 0 1 0 1 1 0 2 1 0 3 1 0 4 1 0 5 L O D

**** **** **** E m p ty V e c to r + D M S O E m p ty V e c to r + D a c la ta s v ir S E C 1 4 L 2 + D M S O S E C 1 4 L 2 + D a c la ta s v ir

Costa et al. unpublished

slide-9
SLIDE 9

Folie 9 Titel

A SNP in Sec14L2 allows replication of all HCV isolates

HCV RNA copies /µl

HCV RNA copy numbers/ ng total RNA *** *** ***

Costa et al., unpublished

Patient samples

slide-10
SLIDE 10

Folie 10 Titel

A model to investigate DAA response before treatment?

Patient A.K.,

  • HCV Genotype 3 Infection
  • OLT in 2009
  • 2x DAA therapy (SOF/RBV und SOF/DAC), no SVR
  • No HCV RASs (at 3 different timepoints)

>300 x GT3 isolate

slide-11
SLIDE 11

Folie 11 Titel

Outlook

  • In vitro testing of all collected samples and correlation

with virological and clinical response

  • Are there other mutations that lead to resistance ?
slide-12
SLIDE 12

Folie 12 Titel

Outline

  • A new in vitro model to predict DAA response?
  • HCV genotyping – Are all results correct?
slide-13
SLIDE 13

Folie 13 Titel

Interlaboratory tests of HCV genotyping (Ringversuch)

  • Ca. 130 labs in Germany have participated (2014/15)

Sample Subtype Identification of HCV- Genotype (N) Subtype (N) correct incorrect correct missing incorrect 375021 1b 126 1 110 15 1 375022 5a 125 2 88 37  375023 3a 123 4 89 33 1 375024 1a 126 1 90 14 22 375025 2b 125 2 85 40  375026 5a 125 6 90 35  375027 3a 129 2 99 30  375028 1a 129 2 101 8 20 375029 1b 129 2 122 6 1 375030 4a 128 3 30 98  Quelle: INSTAND e.V.

slide-14
SLIDE 14

Folie 14 Titel

Which method is the best?

Genotype 1a

Quelle: INSTAND e.V.

slide-15
SLIDE 15

Folie 15 Titel

Which method is the best?

Genotype 1a

Quelle: INSTAND e.V.

slide-16
SLIDE 16

Folie 16 Titel

Summary

  • A mutant in Sec14L2 allows replication of all natural occuring isolates
  • If this model is able to predict the outcome of DAA therapy is currently

under investigation

  • HCV genotyping especially in GT1 patients is –depending on the method that

was used sometimes incorrect

  • Results should be reviewed with a different method in DAA failure
slide-17
SLIDE 17

Folie 17 Titel

AG Ciesek Michael Anspach Tina Bartsch Denisa Bojkova Andreas Clarin Anke Herrmann Nina Kuklinski Antonia Meister Sandra Swoboda Lejla Timmer Verena Wanders Sandra Westhaus

Institut für Molekularbiologie und Klinik für Gastroenterologie, Hepatologie und Endokrinologie

Kooperationspartner

  • T. von Hahn, H. Wedemeyer, MHH, Hannover
  • C. Sarrazin, S. Zeuzem, C. Lange, Universität Frankfurt
  • E. Steinmann, T. Pietschmann, Twincore, Hannover
  • R. Kaiser, Universität Köln
  • K. Lang, A. Paul, F. Helfritz, Universitätsklinikum Essen

Philip Meuleman, Universität Ghent, Belgien

  • U. Protzer, TU / Helmholtz Zentrum München
  • R. Bartenschlager, Universität Heidelberg
  • A. von Brunn, LMU München
  • E. Dazert, Universität Basel, Schweiz

Thank you!